About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

That time of year, need cash to buy her in doors that BIG present ! :)

Total sales still only 4 million as Smiler said people bored of no news choosing which shares to cash in. IMO

Luckypicker - 6 Dec'06 - 12:58 - 14182 of 14203


Just to shut you all up

"John K Pool"
09/11/2006 10:32
To: xxx
cc

Subject
Re: Shareholder Question





Hi
Yes I am currently on the board and no it is all part of a bigger plan
Cheers
John
----- Original Message -----
From: XXX
To: "John K Pool"
Sent: Tuesday, November 07, 2006 4:32 PM
Subject: Re: Shareholder Question


> Dear Mr Pool
>
> Can I ask, is it correct you are on the board of Zyzygy, and why are they
> selling, is this something I should be concerned about.
>
> Also will there be at some point any news on what the conference was
> about,
> as I noted you had put this on your website as to when it was being held,
> but no update as to what was talked about.
>
> Kind regards

cant be long now then

True two weeks and it's xmas!
PH you got one prediction correct.

all i know is significant news is coming, just bleeding impatient now

Its the season to be Jolly :)

Its a bit doom and gloom on the erx thread over on the dark side !

not anymore, its getting exciting, obvious tree shake today, maybe news tomorrow then

news at 3.30

ok but what day and what month !!

Where the news then PH?

PH also post on adv*n (the dark side) as cannoncan he also said 1530 over there !

news at 4.30pm

PH-what are you on???

DONT KNOW WHY ANYBODY TAKES ANY NOTICE OF PH.

HenryFord - 7 Dec'06 - 20:05 - 14498 of 14516

BioMerieux, awarded 54.5m, will focus on the development of new molecular diagnostic platforms to perform high-added-value analyses of infectious diseases and cancers.

http://www.drugresearcher.com/news/ng.asp?n=72476-merieux-alliance-transgene-aii-personalised-medicine-biomerieux

getting back to the RELEVANT RESEARCH

HenryFord - 7 Dec'06 - 20:07 - 14499 of 14516

http://www.investegate.co.uk/Article.aspx?id=200607120700230534G

Cannoncan - 7 Dec'06 - 20:33 - 14500 of 14516 edit

;-)

HenryFord - 7 Dec'06 - 20:44 - 14501 of 14516

You can clearly see the "Personalised Medicine" Potential in the diagnostic side of Eirx. It's on a par commercially with a blockbusting drug down the road.
You can also see that its the Colerectal Cancer Research of Eirx that BioMeriux are clearly after, a collaboration with a $2B sales pa company and reciprocal IP deal is clearly not to be sniffed at.

HenryFord - 8 Dec'06 - 10:40 - 14547 of 14548


from the interview.

"compounds shortly to go into clincical trials and license them out to majors and these are conversations that are progressing at the moment"

"not far off producing efficaious compounds for Colorecteral Cancer"

And intellectual property owners of more than 50% of the known targets in the world.

This was said in June or July?
When the price was 0.3p.
BEFORE we got the Breast Cancer news.

The Bowel Cancer news is likely to be along next, and also the Breast Cancer Compound License news.

Just reminding myself
Thought you research aces would appreciate that!

HenryFord - 8 Dec'06 - 10:43 - 14548 of 14548


and all for 6m. that looks like 20 times too cheap to me

i think this news is pretty major, my reckoning we will get more news than bargained for

HenryFord - 7 Dec'06 - 20:05 - 14498 of 14516

BioMerieux, awarded 54.5m, will focus on the development of new molecular diagnostic platforms to perform high-added-value analyses of infectious diseases and cancers.

http://www.drugresearcher.com/news/ng.asp?n=72476-merieux-alliance-transgene-aii-personalised-medicine-biomerieux

getting back to the RELEVANT RESEARCH

HenryFord - 7 Dec'06 - 20:07 - 14499 of 14516

http://www.investegate.co.uk/Article.aspx?id=200607120700230534G

Cannoncan - 7 Dec'06 - 20:33 - 14500 of 14516 edit

;-)

HenryFord - 7 Dec'06 - 20:44 - 14501 of 14516

You can clearly see the "Personalised Medicine" Potential in the diagnostic side of Eirx. It's on a par commercially with a blockbusting drug down the road.
You can also see that its the Colerectal Cancer Research of Eirx that BioMeriux are clearly after, a collaboration with a $2B sales pa company and reciprocal IP deal is clearly not to be sniffed at.

PH

News at 17.30

(every day on channel 5)